Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy

Published:2019-05-06 Issue:1 Volume:7 Page:
ISSN:2051-1426
Container-title:Journal for ImmunoTherapy of Cancer
language:en
Short-container-title:j. immunotherapy cancer

Author:

Althammer Sonja,Tan Tze Heng,Spitzmüller Andreas,Rognoni Lorenz,Wiestler Tobias,Herz Thomas,Widmaier Moritz,Rebelatto Marlon C.,Kaplon Helene,Damotte Diane,Alifano Marco,Hammond Scott A.,Dieu-Nosjean Marie-Caroline,Ranade Koustubh,Schmidt Guenter,Higgs Brandon W.,Steele Keith E.

Funder

AstraZeneca

Institut National de la Santé et de la Recherche Médicale

Université Pierre et Marie Curie

Université Paris Descartes

MedImmune

Ligue Contre le Cancer

Publisher

BMJ

Subject

Cancer Research,Pharmacology,Oncology,Molecular Medicine,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1186/s40425-019-0589-x.pdf

Reference50 articles.

1. Ilcus C, Bagacean C, Tempescul A, Popescu C, Parvu A, Cenariu M, et al. Immune checkpoint blockade: the role of PD1-PD-L axis in lymphoid malignancies. OncoTargets Ther. 2017;10:2349.

2. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350–5.

3. Brahmer JR, Pardoll DM. Immune checkpoint inhibitors: making immunotherapy a reality for the treatment of lung cancer. Cancer Immunol Res. 2013;1:85–91.

4. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. N Engl J Med. 2015;373:1627–39.

5. Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. N Engl J Med. 2016;375:1823–33.

Cited by 79 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adaptive Responses to PARP Inhibition Predict Response to Olaparib and Durvalumab: Multi-omic Analysis of Serial Biopsies in the AMTEC Trial;2024-08-30

2. Head-to-head comparison of composite and individual biomarkers to predict clinical benefit to PD-1 blockade in non-small cell lung cancer;PLOS ONE;2024-07-31

3. The role of PD-1/PD-L1 signaling pathway in cancer pathogenesis and treatment: a systematic review;Journal of Cancer Metastasis and Treatment;2024-05-28

4. Digital Pathology for Better Clinical Practice;Cancers;2024-04-26

5. Classification of the Tumor Immune Microenvironment Using Machine-Learning-Based CD8 Immunophenotyping As a Potential Biomarker for Immunotherapy and TGF-β Blockade in Nonsmall Cell Lung Cancer;AI in Precision Oncology;2024-04-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3